STOCKHOLM, 21 October, 2019 — Promore Pharma AB (publ) today announced that the company has entered into an agreement with ABG Sundal Collier ASA (“ABGSC”) whereby ABGSC will act as liquidity provider for the Promore Pharma share starting 21 October.
The liquidity provision assignment is offered in accordance with the rules of Nasdaq Stockholm AB’s and means that the liquidity provider quotes a buy and sell volume corresponding to at least 15,000 SEK, with a maximum spread of 4% between the bid and ask price. The purpose is to promote the liquidity in the trading of the share.
For additional information, please contact
Jonas Ekblom, President and CEO
Tel: [+46] 736 777 540
Jenni Björnulfson, CFO
Tel: [+46] 708 55 38 05
The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 CET on 21 October 2019.
Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
Promore Pharma in brief:
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 has initiated a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.